Cargando…
T lymphocyte-targeted immune checkpoint modulation in glioma
Immunomodulatory therapies targeting inhibitory checkpoint molecules have revolutionized the treatment of solid tumor malignancies. Concerns about whether systemic administration of an immune checkpoint inhibitor could impact primary brain tumors were answered with the observation of definitive resp...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7057419/ https://www.ncbi.nlm.nih.gov/pubmed/32051289 http://dx.doi.org/10.1136/jitc-2019-000379 |
_version_ | 1783503651502817280 |
---|---|
author | Kelly, William James Giles, Amber Jin Gilbert, Mark |
author_facet | Kelly, William James Giles, Amber Jin Gilbert, Mark |
author_sort | Kelly, William James |
collection | PubMed |
description | Immunomodulatory therapies targeting inhibitory checkpoint molecules have revolutionized the treatment of solid tumor malignancies. Concerns about whether systemic administration of an immune checkpoint inhibitor could impact primary brain tumors were answered with the observation of definitive responses in pediatric patients harboring hypermutated gliomas. Although initial clinical results in patients with glioblastoma (GBM) were disappointing, recently published results have demonstrated a potential survival benefit in patients with recurrent GBM treated with neoadjuvant programmed cell death protein 1 blockade. While these findings necessitate verification in subsequent studies, they support the possibility of achieving clinical meaningful immune responses in malignant primary brain tumors including GBM, a disease in dire need of additional therapeutic options. There are several challenges involved in treating glioma with immune checkpoint modulators including the immunosuppressive nature of GBM itself with high inhibitory checkpoint expression, the immunoselective blood brain barrier impairing the ability for peripheral lymphocytes to traffic to the tumor microenvironment and the high prevalence of corticosteroid use which suppress lymphocyte activation. However, by simultaneously targeting multiple costimulatory and inhibitory pathways, it may be possible to achieve an effective antitumoral immune response. To this end, there are now several novel agents targeting more recently uncovered “second generation” checkpoint molecules. Given the multiplicity of drugs being considered for combination regimens, an increased understanding of the mechanisms of action and resistance combined with more robust preclinical and early clinical testing will be needed to be able to adequately test these agents. This review summarizes our current understanding of T lymphocyte-modulating checkpoint molecules as it pertains to glioma with the hope for a renewed focus on the most promising therapeutic strategies. |
format | Online Article Text |
id | pubmed-7057419 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | BMJ Publishing Group |
record_format | MEDLINE/PubMed |
spelling | pubmed-70574192020-03-05 T lymphocyte-targeted immune checkpoint modulation in glioma Kelly, William James Giles, Amber Jin Gilbert, Mark J Immunother Cancer Review Immunomodulatory therapies targeting inhibitory checkpoint molecules have revolutionized the treatment of solid tumor malignancies. Concerns about whether systemic administration of an immune checkpoint inhibitor could impact primary brain tumors were answered with the observation of definitive responses in pediatric patients harboring hypermutated gliomas. Although initial clinical results in patients with glioblastoma (GBM) were disappointing, recently published results have demonstrated a potential survival benefit in patients with recurrent GBM treated with neoadjuvant programmed cell death protein 1 blockade. While these findings necessitate verification in subsequent studies, they support the possibility of achieving clinical meaningful immune responses in malignant primary brain tumors including GBM, a disease in dire need of additional therapeutic options. There are several challenges involved in treating glioma with immune checkpoint modulators including the immunosuppressive nature of GBM itself with high inhibitory checkpoint expression, the immunoselective blood brain barrier impairing the ability for peripheral lymphocytes to traffic to the tumor microenvironment and the high prevalence of corticosteroid use which suppress lymphocyte activation. However, by simultaneously targeting multiple costimulatory and inhibitory pathways, it may be possible to achieve an effective antitumoral immune response. To this end, there are now several novel agents targeting more recently uncovered “second generation” checkpoint molecules. Given the multiplicity of drugs being considered for combination regimens, an increased understanding of the mechanisms of action and resistance combined with more robust preclinical and early clinical testing will be needed to be able to adequately test these agents. This review summarizes our current understanding of T lymphocyte-modulating checkpoint molecules as it pertains to glioma with the hope for a renewed focus on the most promising therapeutic strategies. BMJ Publishing Group 2020-02-11 /pmc/articles/PMC7057419/ /pubmed/32051289 http://dx.doi.org/10.1136/jitc-2019-000379 Text en © Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. http://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See http://creativecommons.org/licenses/by-nc/4.0/. |
spellingShingle | Review Kelly, William James Giles, Amber Jin Gilbert, Mark T lymphocyte-targeted immune checkpoint modulation in glioma |
title | T lymphocyte-targeted immune checkpoint modulation in glioma |
title_full | T lymphocyte-targeted immune checkpoint modulation in glioma |
title_fullStr | T lymphocyte-targeted immune checkpoint modulation in glioma |
title_full_unstemmed | T lymphocyte-targeted immune checkpoint modulation in glioma |
title_short | T lymphocyte-targeted immune checkpoint modulation in glioma |
title_sort | t lymphocyte-targeted immune checkpoint modulation in glioma |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7057419/ https://www.ncbi.nlm.nih.gov/pubmed/32051289 http://dx.doi.org/10.1136/jitc-2019-000379 |
work_keys_str_mv | AT kellywilliamjames tlymphocytetargetedimmunecheckpointmodulationinglioma AT gilesamberjin tlymphocytetargetedimmunecheckpointmodulationinglioma AT gilbertmark tlymphocytetargetedimmunecheckpointmodulationinglioma |